BMS-986278
DrugSpecified dose on specified days
NCT Number: NCT06723535
The purpose of this study is to assess the effect of severe renal impairment (RI) and end-stage renal disease (ESRD) with intermittent hemodialysis (IHD) on the pharmacokinetics and safety of BMS-986278. This study plans to use a staged design based on RI severity.
Looking for future studies?
Notify Me18 year–84 year
All sexes
Interventional
Phase 1
Local Institution - 0002, Miami, Florida, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Specified dose on specified days
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to 28 days following discontinuation of dosing
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Bristol-Myers Squibb
Industry
An Open-Label, Single-Dose, Phase 1 Study to Evaluate the Pharmacokinetics and Safety of BMS-986278 in Participants With Normal Renal Function, Participants With Severe Renal Impairment, and Participants With End-Stage Renal Disease on Intermittent Hemodialysis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07426380
Chronic Disease, Disease Attributes
Miami Lakes, Florida, United States
View Trial DetailsNCT04876963
Arrhythmias, Cardiac, Cardiovascular Diseases
Copenhagen, Denmark
View Trial DetailsNCT01380847
Chronic Disease, Disease Attributes
Paris, France
View Trial DetailsNCT01840956
Chronic Disease, Disease Attributes
Durham, North Carolina, United States
View Trial Details